Epidemiology Data Slicer
The ovarian cancer treatment landscape is rapidly evolving, largely due to the introduction of the angiogenesis inhibitor bevacizumab and the PARP inhibitors Lynparza (AstraZeneca / Merck & Co.),…
The ovarian cancer treatment landscape is rapidly evolving, largely due to the introduction of the angiogenesis inhibitor bevacizumab and the PARP inhibitors Lynparza (AstraZeneca / Merck & Co.),…
The treatment of ovarian cancer has historically been dominated by chemotherapy, but angiogenesis and PARP inhibitors are optimizing treatment options. The regulatory approvals of AstraZeneca /…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but with the introduction of Roche / Genentech / Chugai’s angiogenesis inhibitor…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Clarivate Epidemiology’s coverage of ovarian cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of renal…
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP…
The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-…
Chemotherapy remains the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently, PARP inhibitors have entered the…
Market Outlook Targeted therapies are changing the treatment paradigm for ovarian cancer in the top 5 European markets (France, Germany, Italy, Spain, UK). Roche’s Avastin and small-molecule…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…
The premium-priced therapies used to treat ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynparza (AstraZeneca/Merck & Co), Rubraca (Clovis Oncology), and Zejula (…
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy has been the standard of care for ovarian cancer; however, treatment is changing to a targeted approach with…